Prof
- The severity of clinical signs of disease was significantly reduced - The pathological changes in the myelin sheath (demyelination) were not detected - The reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia was observed in the spinal cord tissue - The degree of disability was lowered - The duration of the disease was notably shortened - The percentage mortality in severe disease was radically reduced (70%) - The severity of treatment side effects was low and disappeared after cessation of drug application
The appointment will effectively take place after the review of the current Adequate Disclosure filed with Pink Sheets, and will be reflected in the issuer's next quarterly Adequate Disclosure filing update. The issuer has heard back from Pink Sheets on its original Adequate Disclosure submission. The company's barrister is currently complying with the requests made by the Pink Sheets review staff. The company expects to be in full compliance and to obtain the highest tier ranking of Pink Sheets with the "Current Information" ranking. See: http://www.pinksheets.com/pink/otcguide/investors_market_tiers.jsp shortly.
Dr.
http://www.iss-piran.com/
The International Summer School, Piran,
The company invites any inquiries from qualified medical professionals to contact Dr.
The company intends to provide further updates shortly, and a brief CEO statement from Mr
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com
SOURCE Hard to Treat Diseases